RECOMMENDATIONS FOR USE OF

Chemotherapy for the treatment of advanced breast cancer

A CLINICAL PRACTICE GUIDELINE DEVELOPED BY NATIONAL BREAST AND OVARIAN CANCER CENTRE (NBOCC)

This document supplements guideline recommendation 25 on the use of chemotherapy for the management of advanced breast cancer contained in the National Breast Cancer Centre (NBCC)* Clinical practice guidelines for the management of advanced breast cancer, 2nd edition, 2001 (pages 9–10).1

PURPOSE

This guideline includes statements and recommendations based on available, high-level evidence about the use of chemotherapy for the treatment of advanced breast cancer. The guideline provides health professionals with information designed to help them make management recommendations for improved patient outcomes. NBOCC also develops information specifically for consumers about the diagnosis and treatment of advanced (secondary) breast cancer.

Endorsed by:
BACKGROUND

Advanced breast cancer includes locally advanced and metastatic breast cancer. The goals of treatment in advanced breast cancer are to maximise length of life (overall survival) and quality of life.

There are a number of important components of clinical care for women with advanced breast cancer. These include using anti-cancer treatments to control disease-related symptoms and slow progression of disease, minimising treatment-related toxicity, and reducing the intrusion of the disease and treatment on a woman’s life. Improvements in cancer treatment mean that some women will live for many years after a diagnosis of advanced breast cancer.

The standard systemic treatments for women with advanced breast cancer include chemotherapy, targeted therapy and endocrine therapy.

Chemotherapy drugs used to treat advanced breast cancer include:
• alkylating agents, e.g. cyclophosphamide
• anthracyclines, e.g. doxorubicin, epirubicin
• antimetabolites, e.g. capecitabine, 5-fluorouracil, gemcitabine, methotrexate
• taxanes, e.g. docetaxel, paclitaxel, nab-paclitaxel
• vinorelbine.

Targeted therapies used to treat advanced breast cancer include:
• bevacizumab, lapatinib and trastuzumab.

The selection of specific chemotherapy drugs, combinations, doses, schedules and durations is based on:
• the pathological characteristics of the tumour, especially whether it expresses higher-than-normal levels of the HER2 protein (HER2-positive tumours)
• the clinical characteristics of the tumour, especially its extent and growth rate
• the woman’s past exposure and response to chemotherapy
• co-morbidities
• quality of life considerations including unwanted effects of chemotherapy
• the woman’s preferences
• the woman’s age
• practical considerations.

SUMMARY OF EVIDENCE

The statements and recommendations about the use of chemotherapy for women with advanced breast cancer are based on:
• a review of 63 randomised trials of chemotherapy in metastatic breast cancer published between 2000 and 2007
• a Cochrane review investigating single-agent versus combination chemotherapy for metastatic breast cancer
• a review of randomised trials comparing taxane-containing regimens for metastatic breast cancer
• a review of randomised trials of adding targeted agents to a chemotherapy regimen for metastatic breast cancer.

Additional relevant articles and two significant abstracts, published after the completion of these reviews up until December 2009, have also been considered.

No trials have directly compared chemotherapy with best supportive care in women with advanced breast cancer. Strong indirect evidence that chemotherapy improves survival and quality of life comes from older randomised trials of different doses and durations of chemotherapy, and more recent trials comparing various chemotherapy regimens.

Chemotherapy improves overall survival and quality of life by reducing the tumour size, growth rate or both, in women with responsive tumours. However, chemotherapy can also cause adverse effects.

Differences between the effect of various established chemotherapy drugs and regimens on overall survival are modest in women with advanced breast cancer. Treatment decisions should be based on consideration of the woman’s specific circumstances, attitudes and preferences, as well as pertinent high-quality evidence from randomised trials.

† For a summary of current evidence for endocrine therapy in advanced breast cancer, refer to NBOCC’s Recommendations for use of endocrine therapy for the treatment of hormone receptor-positive advanced breast cancer.
‡ For a summary of current evidence for trastuzumab in advanced breast cancer, refer to NBCC’s Recommendations for use of trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer.

* In February 2008, National Breast Cancer Centre incorporating the Ovarian Cancer Program (NBCC) changed its name to National Breast and Ovarian Cancer Centre (NBOCC)
RECOMMENDATIONS

Please see Appendix 1 (pages 11-14) for statements of evidence on which the following recommendations are based.

Recommendations to individuals should be based on their circumstances, the absolute benefits and harms of treatment, and their personal preferences. These factors should be discussed with the woman. Women receiving chemotherapy should be reviewed regularly and monitored for adverse events.

RECOMMENDATIONS

In women with advanced breast cancer:

There are several specific chemotherapy drugs and/or combinations with similar efficacy in any given situation. In general:

- combination chemotherapy should be considered for women with little or no previous exposure to chemotherapy, widespread or rapidly progressing disease, and few or no co-morbidities
- sequential single-agent chemotherapy should be considered for women with limited or indolent disease, previous exposure to chemotherapy, or significant co-morbidities

In women with visceral hormone receptor-positive disease that is extensive or rapidly progressing, initial chemotherapy should be considered in preference to initial endocrine therapy.

Duration of chemotherapy

Tumour response should be assessed every 6–12 weeks (2–3 cycles) during chemotherapy.

If disease control (stable disease or better) is confirmed and toxicity is tolerable, then chemotherapy should be continued for 18–24 weeks (6–8 cycles).

Extending chemotherapy beyond the standard duration (18–24 weeks; 6–8 cycles) is an option if toxicity is minimal and the goal is to delay progression.

Extending chemotherapy beyond the standard duration has little or no effect on overall survival.

RECOMMENDATIONS

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Cochrane5</td>
</tr>
<tr>
<td>II</td>
<td>Sledge10</td>
</tr>
<tr>
<td>III</td>
<td>Soto11</td>
</tr>
</tbody>
</table>

Taxanes

Single-agent taxanes are an alternative to anthracyclines for first-line treatment for women with advanced breast cancer.

Combination chemotherapy that includes a taxane should be considered for women who have rapidly progressing or extensive visceral disease and limited previous exposure to chemotherapy.

Paclitaxel

The recommended dose and schedule for weekly paclitaxel is 80 mg/m², with a one week break every 4–8 weeks according to toxicity and the woman’s preferences.

The recommended dose for 3-weekly paclitaxel is 175 mg/m² given over 3 hours.

Docetaxel

The recommended dose and schedule for 3-weekly docetaxel is 75–100 mg/m².

Albumin-bound paclitaxel

Nanoparticle albumin-bound paclitaxel is an alternative to 3-weekly paclitaxel, but has not been compared with standard paclitaxel given weekly.

Antimetabolites

Capecitabine as first-line chemotherapy

Single-agent capecitabine is an option for women for whom more intensive chemotherapy is not appropriate.

---

* A recent trial showed that first-line treatment with nab-paclitaxel significantly improved progression-free survival for women with metastatic breast cancer compared with 3-weekly docetaxel.19
Antimetabolites and taxanes

Capecitabine and docetaxel

The combination of capecitabine and docetaxel is an option for women with rapidly progressing or extensive visceral disease, good performance status and limited exposure to previous chemotherapy.

Gemcitabine and paclitaxel

The combination of gemcitabine and paclitaxel is an option for women with rapidly progressing or extensive visceral disease, good performance status and limited exposure to previous chemotherapy.

Targeted therapies

Trastuzumab

Recommendations for women with HER2-positive advanced breast cancer are detailed in NBCC’s guideline Recommendations for use of trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer.

Bevacizumab with first- or second-line chemotherapy for metastatic breast cancer

The routine addition of bevacizumab to chemotherapy is not recommended because the benefits do not outweigh the additional adverse effects.

Lapatinib after progression of disease on trastuzumab

The combination of lapatinib and capecitabine is a good option for women with disease that has progressed after chemotherapy with an anthracycline, a taxane and trastuzumab.

SUMMARY OF TRIAL RESULTS

The most commonly measured efficacy endpoints in chemotherapy trials are tumour response rate, progression-free survival and overall survival. Of these, the most critical is overall survival. The evidence that chemotherapy improves overall survival in advanced breast cancer is indirect but compelling. However, significant benefits seen in overall survival for one chemotherapy regimen over another are relatively small in clinical trials. Superiority for these endpoints of one regimen over another will also influence treatment decisions, particularly where disease is rapidly progressing and a quick response is necessary.

Both quality of life and treatment toxicity are important factors to be considered. While toxicity is generally well-recorded in clinical trials, quality of life is less frequently measured and the reported analyses of quality of life data are often superficial.

Overall survival

A review of 63 trials, including over 21,000 women, identified eight trials that reported a statistically significant overall survival benefit ranging from 3-7 months (see Table 1).

### Table 1. Chemotherapy trials in advanced breast cancer with an overall survival benefit (p<0.05)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Arm A</th>
<th>Arm B</th>
<th>Number of patients(n)</th>
<th>OS Arm A (months)</th>
<th>OS Arm B (months)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feher 2005</td>
<td>Epirubicin</td>
<td>Gemcitabine</td>
<td>410</td>
<td>19.1</td>
<td>11.8</td>
<td>0.0004</td>
</tr>
<tr>
<td>O'Shaughnessy</td>
<td>Docetaxel/</td>
<td>Gemcitabine</td>
<td>511</td>
<td>14.5</td>
<td>11.5</td>
<td>0.01</td>
</tr>
<tr>
<td>2002</td>
<td>capecitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jassem 2001</td>
<td>Doxorubicin/</td>
<td>FAC</td>
<td>267</td>
<td>23.3</td>
<td>18.3</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>paclitaxel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albain 2008</td>
<td>Paclitaxel/</td>
<td>Paclitaxel</td>
<td>529</td>
<td>18.5</td>
<td>15.8</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>cmcitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bontenbal 2005</td>
<td>Docetaxel/</td>
<td>FAC</td>
<td>216</td>
<td>22.6</td>
<td>16.2</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>doxorubicin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stockler 2007</td>
<td>Intermittent or continuous</td>
<td>CMF</td>
<td>325</td>
<td>22.0</td>
<td>18.0</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>capecitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jones 2005</td>
<td>Docetaxel</td>
<td>Paclitaxel</td>
<td>449</td>
<td>15.4</td>
<td>12.7</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Icli 2005</td>
<td>Oral etoposide/cisplatin</td>
<td>Paclitaxel</td>
<td>201</td>
<td>14.0</td>
<td>9.5</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Notes: OS = overall survival; FAC = 5-fluorouracil/doxorubicin/cyclophosphamide; CMF = cyclophosphamide/methotrexate/5-fluorouracil
A Cochrane meta-analysis found that combination chemotherapy improved tumour response rates, time to progression and overall survival, but was associated with higher rates of toxicity, compared with single-agent chemotherapy. However, very few such trials specifically compared a combination regimen with the sequential use of the component agents. In two trials that did so, differences in time to progression (after both drugs) and overall survival were not seen, suggesting that the sequential use of single agents is safe and effective in the absence of rapidly progressive disease.

Older trials have shown that lower-than-standard doses or very short durations of chemotherapy may be associated with reduced overall survival compared to standard doses. A Cochrane review showed that very high dose chemotherapy did not improve overall survival and a 2008 meta-analysis found that extending chemotherapy beyond the standard duration (18–24 weeks) had little effect on overall survival. Thus optimal overall survival is achieved when standard doses and durations of conventional drug regimens are used.

Progression-free survival and response rate

In trials published between 2000 and 2007, 22 trials reported statistically significant differences in progression-free survival, and 19 trials reported significant differences in response rate. Considered together, these trials showed improved progression-free survival or response rates for combinations compared with single agents, anthracyclines compared with non-anthracycline regimens, and taxanes compared with non-taxane regimens.

**Targeted therapies**

How best to incorporate targeted therapies into chemotherapy regimens is the subject of ongoing trials. Trials testing the addition of lapatinib or bevacizumab have demonstrated some clinical benefits, but not differences in overall survival. A trial in women with HER2-positive breast cancer that had progressed after trastuzumab, showed that the addition of lapatinib to capecitabine improved response rate and time to progression, but not overall survival, compared with capecitabine alone.

**Quality of life**

Only a third of the 63 trials identified in the 2000-2007 review mentioned formal quality of life measurements in the abstract. While toxicity is sometimes used as a surrogate for quality of life, two important older trials showed that toxicity and quality of life are not always closely linked. These trials showed that strategies to limit toxicity (by lowering either the dose or duration of chemotherapy) led to decreased quality of life.

<table>
<thead>
<tr>
<th>CLASS/AGENT</th>
<th>CHARACTERISTIC SIDE EFFECTS OF COMMON CHEMOTHERAPY DRUGS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alkylating agents</strong></td>
<td>Bladder irritation, fatigue, hair loss, lowered blood counts, nausea/vomiting</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td></td>
</tr>
<tr>
<td><strong>Anthracyclines</strong></td>
<td>Cardiac toxicity, fatigue, lowered blood counts, mouth ulcers, nausea/vomiting</td>
</tr>
<tr>
<td>Doxorubicin, epirubicin</td>
<td></td>
</tr>
<tr>
<td><strong>Antimetabolites</strong></td>
<td>Diarrhoea, fatigue, hand-foot syndrome, nausea, stomatitis</td>
</tr>
<tr>
<td>Capecitabine</td>
<td></td>
</tr>
<tr>
<td><strong>Taxanes</strong></td>
<td>Allergic reactions (paclitaxel), fatigue, hair loss, lowered blood counts, muscle aches, neurological damage</td>
</tr>
<tr>
<td>Docetaxel, paclitaxel</td>
<td></td>
</tr>
<tr>
<td><strong>Vinorelbine</strong></td>
<td>Fatigue, injection site pain, hair loss (moderate), lowered blood counts, neuropathy</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Targeted therapies</strong></td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Cerebrovascular ischemia, fatigue, headache, hypertension, infection, sensory neuropathy, proteinuria</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Diarrhoea, dyspepsia, fatigue, hand-foot syndrome, nausea/vomiting, rash</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>Anaemia, cardiac dysfunction, infection, leukopenia, neutropenia</td>
</tr>
</tbody>
</table>
STRENGTHS AND WEAKNESSES OF THE EVIDENCE

The main strength of the evidence reviewed is the long history of well-conducted randomised trials testing different chemotherapy strategies in advanced breast cancer. A major limitation of the evidence is the paucity of data about the effects of different treatments on quality of life and symptom control.

UNANSWERED QUESTIONS

Important unanswered questions about the use of chemotherapy in advanced breast cancer are outlined below:

- What is the optimal duration of chemotherapy, especially when combined with targeted therapy?
- How would clinical outcomes improve by individualising chemotherapy according to laboratory measures of tumour sensitivity?
- What is the significance of changes in tumour markers and genetic profiling for use of chemotherapy?
- What is the optimal duration of targeted therapy when combined with chemotherapy?
- What evidence is available from clinical trials for treatment of metastatic breast cancer beyond the first-line setting?
- What are the quality of life and symptom control issues associated with the use of chemotherapy?
- How could chemotherapy be used in association with endocrine therapies and supportive therapies?
- When disease progresses, when should targeted therapies be discontinued?

APPENDIX 1

STATEMENTS OF EVIDENCE

The following statements of evidence support the NBOCC recommendations for use of chemotherapy for the treatment of advanced breast cancer (pages 4-6).

<table>
<thead>
<tr>
<th>STATEMENTS</th>
<th>LEVEL OF EVIDENCE</th>
<th>REFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In women with advanced breast cancer:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination chemotherapy increases response rates, time to progression, toxicity and overall survival, compared with single-agent chemotherapy, not including sequential use of the same drugs</td>
<td>I</td>
<td>Cochrane^5</td>
</tr>
<tr>
<td>Combination chemotherapy increases response rates and toxicity, but not time to progression or overall survival, compared with sequential use of the same drugs as single agents</td>
<td>II</td>
<td>Sledge^10 Soto^11</td>
</tr>
<tr>
<td>In women with hormone receptor-positive disease:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• initial chemotherapy achieves similar overall survival to initial endocrine therapy, except in those with visceral disease that is extensive or rapidly progressing, where initial chemotherapy shows improved survival</td>
<td>I</td>
<td>Cochrane^5</td>
</tr>
<tr>
<td>• endocrine therapy has fewer adverse effects than chemotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Higher-than-standard doses of chemotherapy increase tumour response and toxicity, but not time to progression or overall survival, compared with standard doses</td>
<td>I</td>
<td>Cochrane^5</td>
</tr>
<tr>
<td>Lower-than-standard doses of chemotherapy do not improve quality of life and survival, compared with standard doses</td>
<td>II</td>
<td>Tannock^37</td>
</tr>
<tr>
<td>Duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extending chemotherapy beyond the standard duration (18–24 weeks; 6-8 cycles) delays progression but has limited effect on overall survival</td>
<td>I</td>
<td>Gennari^12</td>
</tr>
<tr>
<td>Shorter-than-standard durations (&lt;18-24 weeks) of chemotherapy result in reduced overall survival and quality of life</td>
<td>II</td>
<td>Coates^36</td>
</tr>
</tbody>
</table>
**State of the art**

**Taxanes**

Single-agent taxanes give similar response rates and overall survival, but shorter time to progression compared with anthracyclines

Taxane-based combination chemotherapy increases response rates and time to progression, but not overall survival, compared with anthracyclines

**Paclitaxel**

When compared with 3-weekly paclitaxel, use of weekly paclitaxel:

- increases time to progression and overall survival
- causes less myelosuppression, but more neuropathy
- requires more clinic visits

For 3-weekly paclitaxel:

- increasing the dose beyond 175mg/m² increases toxicity, but not response rate, survival or quality of life

**Docetaxel**

For 3-weekly docetaxel:

- increasing the dose from 75 mg/m² to 100 mg/m² increases response rates and toxicity, but not time to progression or overall survival
- reducing the dose from 75 mg/m² to 60 mg/m² decreases toxicity

**Docetaxel versus paclitaxel**

3-weekly docetaxel and weekly paclitaxel both increase response rates, time to progression and overall survival, when compared with 3-weekly paclitaxel

No randomised trials in advanced breast cancer have directly compared 3-weekly docetaxel with weekly paclitaxel

When compared with paclitaxel, docetaxel causes:

- more myelosuppression and gastrointestinal toxicity
- less neuropathy and allergic reactions

**Albumin-bound paclitaxel**

When compared with standard 3-weekly paclitaxel, nanoparticle albumin-bound paclitaxel:

- increases response rate and time to progression, but not overall survival
- causes more neuropathy, fatigue and gastrointestinal toxicity, but less neutropenia and allergic reactions

Nanoparticle albumin-bound paclitaxel has not been compared with standard paclitaxel given weekly

**Antimetabolites**

**Capecitabine as first-line chemotherapy for metastatic breast cancer**

For women for whom more intensive chemotherapy is not appropriate, capecitabine improves overall survival and is better tolerated than oral cyclophosphamide, methotrexate and fluorouracil SFU (CMF)

**Antimetabolites and taxanes**

**Capecitabine and docetaxel**

In women previously treated with an anthracycline, the combination of capecitabine and docetaxel, compared with single-agent 3-weekly docetaxel:

- increases response rates, time to progression and overall survival
- increases toxicity

**Gemcitabine and paclitaxel**

In women previously treated with an anthracycline, the combination of gemcitabine and paclitaxel, compared with single-agent 3-weekly paclitaxel:

- increases response rate, time to progression and overall survival
- increases toxicity
### Targeted therapies

<table>
<thead>
<tr>
<th>Therapeutics</th>
<th>Level of Evidence</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trastuzumab</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For women with HER2-positive advanced breast cancer, see NBCC’s guideline <em>Recommendations for use of trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Bevacizumab with first-line chemotherapy for metastatic breast cancer** |
| When compared with weekly paclitaxel alone, the addition of bevacizumab: |
| • improves response rates and time to progression, but not overall survival |
| • causes more hypertension and proteinuria |
| When compared with 3-weekly docetaxel alone, the addition of bevacizumab: |
| • improves response rates and time to progression, but not overall survival |
| • causes more febrile neutropenia |

| **Bevacizumab with second- or third-line chemotherapy for metastatic breast cancer** |
| In women previously treated with an anthracycline and taxane, the addition of bevacizumab to capecitabine, compared with capecitabine alone: |
| • improves response rates, but not time to progression or overall survival |
| • causes more hypertension, proteinuria and hand-foot syndrome |

| **Lapatinib after progression on trastuzumab** |
| When compared with capecitabine alone, the addition of lapatinib after progression on trastuzumab: |
| • improves response rates and time to progression, but not overall survival |
| • causes more diarrhoea, dyspepsia, liver dysfunction and rash |

### REFERENCES

7. University of South Australia Sansom Institute. Addition of targeted therapies (bevacizumab and lapatinib) to a chemotherapy regimen for metastatic breast cancer. Adelaide: University of South Australia Sansom Institute; 2008.*

*Available on request from NBOCC*


ACKNOWLEDGEMENTS

Membership of NBOCC Chemotherapy Working Group
This guideline was developed by a multidisciplinary working group convened by NBOCC.

Associate Professor Martin Stockler Medical Oncologist (Chair)
Dr Arlene Chan Medical Oncologist
Ms Sally Crossing AM Consumer Representative
Ms Jennifer Muller Consumer Representative
Ms Kathy Watty Breast Nurse Coordinator
Dr Nicholas Wilcken Medical Oncologist

Membership of NBOCC Advanced Breast Cancer Guidelines Working Group
The development of this guideline was overseen by a multidisciplinary working group convened by NBOCC: Dr Karen Luxford (Facilitator), Dr David Blakey, Professor Phyllis Butow, Ms Helen Collyer (deceased), Ms Sally Crossing AM, Associate Professor Jane Dahlstrom, Dr Craig Murphy, Ms Janet Rice, Dr Catherine Shannon, Ms Ann Town (deceased), Professor Patsy Yates.

NBOCC Staff
Ms Ornella Care Program Manager
Ms Emma Lonsdale Project Officer
Ms Alison Pearce Program Manager

Systematic Reviews
NBOCC gratefully acknowledges the work of Dr Nicholas Wilcken and Dr Rachel Dear at Westmead Hospital and Dr Agnes Vitry at the University of South Australia Sansom Institute in developing systematic reviews, which informed this guideline.

External Review
NBOCC acknowledges those who gave their time to provide comment on the draft guideline recommendations as part of the external review process.

Acknowledgement
The National Breast Cancer Foundation provided funding for the development of this guideline.

Pharmaceutical Benefits Scheme listings for drugs mentioned in this guideline for the treatment of advanced or metastatic breast cancer are available at www.pbs.gov.au

The Herceptin® Program
Trastuzumab is subsidised (via The Herceptin® Program funded by the Australian Government: www.medicareaustralia.gov.au) for the treatment of patients with HER2-positive metastatic breast cancer:

- in combination with taxanes, for patients who have not received chemotherapy for metastatic disease, or
- as monotherapy, for treatment of patients who have received one or more chemotherapy regimen(s) for metastatic disease.

Recommendations for use of chemotherapy for the treatment of advanced breast cancer was prepared and produced by:
National Breast and Ovarian Cancer Centre
Level 1 Suite 103/355 Crown Street Surry Hills NSW 2010
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 Freecall 1800 624 973
Website: www.nbocc.org.au

© National Breast and Ovarian Cancer Centre 2010

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part might be reproduced by any process without prior written permission from National Breast and Ovarian Cancer Centre. Requests and enquiries concerning reproduction and rights should be addressed to the Corporate Communications Manager, National Breast and Ovarian Cancer Centre.

Copies of this resource can be downloaded from the National Breast and Ovarian Cancer Centre website: www.nbocc.org.au.

Recommended citation

Disclaimer
National Breast and Ovarian Cancer Centre does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. National Breast and Ovarian Cancer Centre develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.

National Breast and Ovarian Cancer Centre is funded by the Australian Government Department of Health and Ageing.